Intratumoral Immunotherapy for Cancer: Update 2024 of a Novel Approach
David G. Bostwick, MD, MBA, FCAP, discusses the potential of intratumoral immunotherapy in treating prostate cancer.
Read MoreSelect Page
Posted by David G. Bostwick, MD, MBA, FCAP | Mar 2025
David G. Bostwick, MD, MBA, FCAP, discusses the potential of intratumoral immunotherapy in treating prostate cancer.
Read MorePosted by Alan H. Bryce, MD | Mar 2025
Alan H. Bryce, MD, delves into the critical role of genetic testing in prostate cancer management.
Read MorePosted by David M. Albala, MD | Mar 2025
David M. Albala, MD, explores telesurgery, highlighting its technological advancements, ethical considerations, and clinical potential.
Read MorePosted by Robert Dreicer, MD, MS, MACP, FASCO | Mar 2025
Robert Dreicer, MD, MS, MACP, FASCO, highlights the complexities of managing high-grade urothelial carcinoma of the upper tract.
Read MorePosted by Daniel P. Petrylak, MD | Feb 2025
Daniel P. Petrylak, MD, analyzes bladder cancer treatment advancements, emphasizing recent clinical practice breakthroughs and challenges.
Read More